Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin plus Sunitinib in Metastatic Renal Cell Carcinoma
NCT00709995Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2008
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of enzastaurin in metastatic renal cell carcinoma (mRCC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression Free Survival up to 24 Months. Started Jun 2008; status: completed.
02
Drugs
enzastaurin
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00709995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00709995.